SANUWAVE Health reports preliminary Q1 2025 revenue of $9.1M-$9.3M, up 57-61% YoY

SANUWAVE Health, Inc.

2025-Q1 EPS reported -$0.66 revenue$9,342,000

Preliminary Q1 2025 revenue $9.1M-$9.3M, highest Q1 in company history; +57-61% vs Q1 2024.
UltraMIST revenue up >65% YoY, constitutes ~99% of total revenues.
Results slightly above upper end of guidance given in Q4 2024 earnings release (March 21, 2025).
CEO Morgan Frank notes sales force restructuring complete; all manufacturing domestic, no significant tariff impact.
Full Q1 2025 results expected around May 9, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.